{"task_id": "07db6ffb619ed4fe", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 279/464)", "text": "intolerant of amphotericin B\n268\nAntifungal Agents\n\n--- Page 290 ---\nINDICATIONS FOR CASPOFUNGIN\nINVASIVE ASPERGILLOSIS\nthird line treatment for\npatients who are refractory or intolerant of voricona\nzole (first line) or amphotericin B (second line)\nINVASIVE CANDIDIASIS\nsecond or third line treat\nment for patients who are refractory or intolerant of\nfluconazole (first line for some) or amphotericin B (first\nline for others)\nFUNGEMIA\nempiric treatment for fungi not yet\nspeciated where neither amphotericin B nor flucona\nzole can be used\nFEBRILE NEUTROPENIA\nempiric antifungal treat\nment for patients intolerant of amphotericin B\nTREATMENT DEFINITIONS\nREFRACTORY\npersistence of positive cultures OR\nlack of clinical response despite \u00035 days of therapy\nand removal of catheter if applicable\nINTOLERANCE\ndoubling from baseline and serum\nCr \u0003450 mmol/L [\u00035.1 mg/dL], creatinine clearance\n\u000440 mL/min or concomitant administration of nephro\ntoxins, tripling of serum creatinine from baseline, docu\nmented allergy, or intolerable infusion reactions\nInfection Control\nNOSOCOMIAL INFECTIONS\nDEFINITION\ninfections acquired in hospital that\noccur between 72 h after admission and 72 h after\ndischarge (up to 30 days for surgical procedures)\nURINARY TRACT INFECTIONS\nsecondary to urin\nary catheters. Infection rates are 1 5%, up to 100%\nfor long term catheterization. Complications include\ncystitis, prostatitis, pyelonephritis, and urosepsis\nVENTILATOR ASSOCIATED\nPNEUMONIAS\nsec\nondary to endotracheal tube insertion (>48h, p. 94)\nBACTEREMIA\nsecondary to central venous cathe\nters. Infection rates are 3 7%\nSURGICAL SITE INFECTIONS\nsecondary to incisions\nPREVENTION STRATEGIES\nhand washing, hand\nwashing, and hand washing. Education, isolation,\nand surveillance are important. Practice routine/stan\ndard/universal precautions with the use of gloves\nwhen handling all body fluids except sweat. Always\nuse sterile technique when inserting urinary and\ncentral venous catheters. Minimize NG tube insertion\nand keep patient erect if intubated\nISOLATION\n\u0002\nAIRBORNE (negative pressure room with high effi\nciency particulate aerator filter, certified N95\nrespirator\nfor\npersonal\nprotection)\nvaricella,\ntuberculosis. Negative pressure room required\n\u0002\nDROPLET (mask within 3 6 feet; eye protection)\nH. influenzae, N. meningitidis, influenza, RSV, pertussis\n\u0002\nCONTACT (glove, gown, wash hands)\nC. difficile,\nVRE, MRSA\nN. MENINGITIDIS PROPHYLAXIS\n\u0002\nCHEMOPROPHYLAXIS\nfor exposures in last 7 days\nwith ciprofloxacin 500 mg PO \u00051 dose or rifampin\n600 mg PO BID \u00052 days can be used to reduce the\nrisk of N. meningitidis in \u2018close contacts.\u2019\u2019 Vaccines\nare not recommended for primary prophylaxis\npost exposure, but may be useful for epidemic\ncontrol on a population basis\nNOSOCOMIAL INFECTIONS (CONT\u2019D)\n\u0002\nCLOSE CONTACTS\ndefined as healthcare workers\nwith direct exposure to respiratory secretions\n(e.g. mouth to mouth resuscitation or intubation),\nhousehold members, intimate contacts, children in\nschool environments, coworkers in the same office,\nyoung adults in dormitories, and recruits in train\ning centers. Not recommended for most medical\npersonnel (i.e. those without direct exposure to\npatient\u2019s oral secretions) or for casual or indirect\ncontacts (e.g. school or workmates)\nNEEDLE STICK INJURY\nPREVENTION\nroutine/standard/universal\nprecau\ntions (gloves, gowns, masks if risk of exposure of\nbody fluids), never recap needles, education\nPRE EXPOSUREPROPHYLAXIS\nimmunization(hepa\ntitis B vaccine at 0, 1, 6 months, influenza)\nRISK OF TRANSMISSION\ndepends on the mechan\nism of exposure, source patient characteristics, pre\nand post exposure prophylaxis\n\u0002 HBV\n6 30% if source positive. Transmission via\nurine, feces, and saliva unlikely\n\u0002 HCV\n1.8% if source positive. Transmission via\nurine and feces unlikely\n\u0002 HIV\n0.3% if source positive. Transmission via\nurine, feces, and saliva unlikely\nPOST EXPOSURE PROCEDURE\n\u0002\nSOURCE PATIENT TESTING\nHBV, HCV, HIV\n\u0002\nEXPOSED PERSON BASELINE TESTING\nHBV, HCV, HIV\n(ELISA, Western), CBCD, lytes, urea, Cr, AST, ALT,\nALP, bili\n\u0002 HBV PROPHYLAXIS\nHB Ig (only if source patient\nis HBsAg positive or unknown and the exposed\nperson is unvaccinated) and start vaccination for HBV\n\u0002 HIV PROPHYLAXIS\nantiretroviral (if source patient\nHIV positive). Therapy may include zidovudine and\nlamivudine \u0006 protease inhibitor such as lopinavir/\nInfection Control\n269", "text_length": 4365, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 279/464)", "type": "chunk", "chunk_index": 278, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.629688", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.630393", "status": "complete", "chunks_added": 3}